Enliven Therapeutics
ELVN
17 hedge funds and large institutions have $174M invested in Enliven Therapeutics in 2020 Q1 according to their latest regulatory filings, with 17 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
65.54% more ownership
Funds ownership: 0% → 65.54% (+66%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$64M |
| 2 |
OrbiMed
New York
|
+$43.3M |
| 3 |
RA Capital Management
Boston,
Massachusetts
|
+$23.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.1M |
| 5 |
Deerfield Management
New York
|
+$7.96M |
Top Sellers
ELVN Hedge Fund Activity: Q1 2020 in Review
17 of the 4,549 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q1 2020, worth a combined $174M.
Buyers outnumbered sellers: 17 funds opened new ELVN positions and 0 closed out — a net gain of 17 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $64M.
- 17 institutional investors held Enliven Therapeutics (ELVN) as of Q1 2020, up from 0 in Q4 2019.
- Funds reported $174M of Enliven Therapeutics stock for Q1 2020.
- 17 funds opened new Enliven Therapeutics positions in Q1 2020 and 0 closed out, a net change of +17 holders.
- The largest Enliven Therapeutics buyer in Q1 2020 was NEA Management Company, an estimated $64M added.
Based on aggregated 13F filings for Q1 2020.